MedPath

Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study

Not Applicable
Completed
Conditions
Cancer
Interventions
Behavioral: Standard endurance training
Behavioral: Standard resistance training
Behavioral: Daily undulating periodization resistance training
Behavioral: Polarized endurance training
Registration Number
NCT02883699
Lead Sponsor
University Hospital Heidelberg
Brief Summary

The TOP Study is a two-stage study on individually tailored endurance and resistance training prescriptions for breast and prostate cancer patients after the end of primary therapy in order to optimize training effects.

Detailed Description

The TOP Study is a two-stage study on individually tailored endurance and resistance training prescriptions for breast and prostate cancer patients after the end of primary therapy in order to optimize training effects.

The TOP Study Part I aims at identifying the most appropriate way of individual intensity prescription. In a descriptive cross sectional study, 20 breast and 20 prostate cancer patients perform singe endurance and resistance training sessions prescribed by means of different methods of intensity prescription. The most appropriate method of intensity prescription is identified through considering predictability/homogeneity of physiological responses as well as perceived exertion and enjoyment.

The TOP Study Part II aims at investigating the most effective training method in terms of enhancing physical fitness for both endurance and strength training. The design is an exploratory four-arm 12-week randomized controlled training intervention trial in 60 breast and 60 prostate cancer patients. In two endurance arms, vigorous continuous training is compared to a polarized program consisting of moderate training and aerobic high intensity interval training (HIIT). Similarly, in two resistance training arms, standard machine based hypertrophy training is compared to training following a daily undulating periodization design.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
132
Inclusion Criteria
  • diagnosed with early stage breast cancer (M0) or prostate cancer (M0 or M1 with PSA evidence of stable disease)
  • 6 to 52 weeks after the end of primary therapy
  • ≥18 to 75 years of age
  • no regular endurance or resistance training (≥ one session per week) since diagnosis or within the last 6 months
  • sufficient German language skills
  • willing/ able to train at the provided exercise facilities twice per week and to take part in the scheduled testing
  • signed informed consent.
Exclusion Criteria
  • diagnosed with additional other cancer
  • brain or bone metastases in M1 prostate cancer patients
  • heart failure >NYHA III, unstable angina pectoris or severe arrhythmia
  • uncontrolled hypertension
  • reduced standing or walking ability
  • any other comorbidities that preclude participation in exercise testing or training.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Endurance Training Group 1Standard endurance trainingStandard endurance training
Resistance Training Group 1Standard resistance trainingStandard resistance training
Resistance Training Group 2Daily undulating periodization resistance trainingDaily undulating periodization resistance training
Endurance Training Group 2Polarized endurance trainingPolarized endurance training
Primary Outcome Measures
NameTimeMethod
Change in maximal oxygen uptake (VO2peak) (endurance training groups only)12 weeks

Change in maximal oxygen uptake (VO2peak) assessed in a maximal incremental exercise test (CPET) on a cycle ergometer

Change in one repetition maximum (1RM) of the knee extensors (resistance training groups only)12 weeks

Change in one repetition maximum (1RM) of the knee extensors in a machine based 1RM test

Change in maximal isokinetic peak torque (MIPT) of the knee extensors (resistance training groups only)12 weeks

Change in maximal isokinetic peak torque (MIPT) of the knee extensors assessed in a stationary dynamometer test

Secondary Outcome Measures
NameTimeMethod
Change in peak power output (PPO) (endurance training groups only)12 weeks

Change in peak power output (PPO) assessed in a maximal incremental exercise test (CPET) on a cycle ergometer

Change in blood lactate threshold (endurance training groups only)12 weeks

Change in blood lactate threshold assessed in a maximal incremental exercise test (CPET) on a cycle ergometer

Change in ventilatory threshold (endurance training groups only)12 weeks

Change in ventilatory threshold assessed in a maximal incremental exercise test (CPET) on a cycle ergometer

Change in maximum voluntary isometric contraction (MVIC) of the knee extensors (resistance training groups only)12 weeks

Change in maximum voluntary isometric contraction (MVIC) of the knee extensors assessed in a stationary dynamometer test

Change in total work (TW) of the knee extensors12 weeks

Change in total work (TW) of the knee extensors assessed in a stationary dynamometer test

Change in muscular fatigue index (FI%) of the knee extensors12 weeks

Change in muscular fatigue index (FI%) of the knee extensors assessed in a stationary dynamometer test

Adherence to the training programs12 weeks

Adherence to the training programs

Drop-out rate in the training groups12 weeks

Drop-out rate in the training groups

Pain during and between training sessions12 weeks

Pain during and between training sessions (Brief Pain Inventory, BPI)

Minor and major adverse events during training sessions12 weeks

Minor and major adverse events during training sessions

Changes in fatigue12 weeks

Changes in fatigue (Multidimensional Fatigue Inventory, MFI 20)

Changes in Quality of Life (QoL)12 weeks

Changes in Quality of Life (QoL) (European Research and Treatment in Cancer Quality of Life Questionnaire, EORTC QLQ-C30)

Changes in depression12 weeks

Changes in depression (Center for Epidemiologic Studies Depression Scale, CES-D)

Enjoyment of the training programs12 weeks

Enjoyment of the training programs (according to Rogers)

Trial Locations

Locations (1)

Heidelberg University Clinic

🇩🇪

Heidelberg, Germany

© Copyright 2025. All Rights Reserved by MedPath